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The aim of the present study was to investigate P300 event-
related potential components in euthymic bipolar disorder
type I (BDI) and bipolar disorder type II (BDII) patients and
matched controls. A total of 10 BDI patients, 10 BDII
patients and 10 healthy individuals were enrolled in the
study. Event-related potential data were collected according
to a standard auditory ‘oddball’ paradigm. A significant
groups effect in both the peak amplitude (P< 0.001) and the
mean amplitude (P<0.001) was observed; post-hoc
comparisons showed that the peak and mean amplitudes of
BDI and BDII patients were significantly lower than the peak
and mean amplitudes of the healthy controls. The
neurophysiological patterns found in the present study
might at least partially reflect the presence of a mild
selective cognitive impairment in euthymic BDI and BDII
patients. From a clinical point of view, these evidences
support the potential role of cognitive interventions in the
treatment of BD. NeuroReport 26:206–210 Copyright ©
2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Bipolar disorder (BD) is a chronic and disabling disorder
characterized by manic/hypomanic and depressive epi-
sodes [1]. The course of BD has traditionally been
viewed as episodic, with symptomatic and functional
recovery between mood episodes; however, recent clin-
ical and epidemiological studies document how, despite
symptomatic improvements or recovery following mood
episodes, many BD individuals experience cognitive
disturbances even during the euthymic phase of the
disease [2–7].
Both the 4th and the 5th edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM) divide BD
into two types labelled as bipolar disorder type I (BDI)
and bipolar disorder type II (BDII) [1,8,9]; BDI is
defined by manic or mixed episodes that last at least
7 days or by manic symptoms that are so severe that the
patient needs immediate hospital care, whereas BDII is
defined by a pattern of depressive and hypomanic epi-
sodes, but no full-blown manic or mixed episodes [1,8,9].
Cognitive disturbances may affect patients with both the
subtypes of BD [5,6]; in particular, it has been reported
that BDII patients show a level of neuropsychological
performances intermediate between BDI and healthy
individuals, specifically in frontal executive functioning
and verbal learning working memory [6].
From a neurophysiological point of view, event-related
potentials (ERPs) allow the identification of specific neu-
rocognitive deficiencies [10,11]. In particular, the P300
component has been studied widely and it is believed to
be related to stimuli categorization as an indicator of
selective attention and memory updating [10]. The P300
consists of two main subcomponents named P3a and P3b;
whereas the p3a, which is elicited by a distracter stimulus,
has been interpreted as a neural correlate of the orienting
response, the P3b component, which is elicited by a target
rare stimulus, reflects neuronal activity associated with
revision of the mental representation of the previous event
within the stimulus environment [10].
This component has been found to be abnormal in a
range of psychiatric afflictions including BD; in particular,
the reduction in the amplitude of P300 components
represents the most common neurophysiological
abnormality observed in euthymic BD patients [12–15].
However, most of the studies considered only BDI
patients or did not consider the two subtypes of BD
patients independently; in addition, no studies have so
far carried out a comparison of P300 components
between euthymic BDI patients, BDII patients and
matched healthy controls.
Given the above, the aim of the present paper was to
evaluate the differences in P3b components between
206 Clinical neuroscience
0959-4965 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/WNR.0000000000000329
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
patients with BDI, BDII and healthy controls. It is
hypothesized that, similar to what has previously been
found in relation to neuropsychological disturbances [6],
BDII patients may show neurophysiological character-
istics intermediate between BDI patients and healthy
individuals.
Materials and methods
Participants
A total of 10 BDI patients (four men and six women, aged
31–64 years mean age: 47.20 ± 8.90) and 10 BDII patients
(four men and six women, aged 33–65 years mean age:
48.50 ± 14.26) referring at the Policlinico Umberto I
University Hospital, Sapienza University of Rome, were
consecutively enrolled in the study. Patients were diag-
nosed using research modules of the Structured Clinical
Interview for the DSM-IV [16]; they were in the euthy-
mic phase of the disease, as assessed by Hamilton
Depression Rating Scale score less than 7 [17] and Young
Mania Rating Scale less than 7 [18].
A control group of healthy individuals (with no Axis I and
II DSM-IV diagnosis) comparable for age and sex was
also included (four men and six women, aged 31–65 years
mean age: 46.20 ± 13.05). Patients’ exclusion criteria were
as follows: left handedness, history of neurologic dis-
eases, other Axis I diagnosis, hospitalization in the last
12 months, patients on stable pharmacological treatment
from at least 2 months, pharmacological treatment with
typical antipsychotics, presence of electroencephalo-
graphic (EEG) abnormalities at the baseline recording,
Hamilton Depression Rating Scale score greater than 7,
Young Mania Rating Scale greater than 7 and mental
retardation (IQ< 70) measured by Raven Progressive
Matrices (PM38) [19].
The research protocol was approved by the Ethical
Committee of Human Experimentation of Policlinico
Umberto I University Hospital; after receiving informa-
tion on the aims of the study, all participants provided
their written consent.
EEG recording and event-related potentials
The ERP data were collected according to a standard
auditory ‘oddball’ paradigm consisting of a sequence
of two tones (duration: 200ms; rise–fall times: 10 ms;
intensity: 80 dB SPL) delivered in a random order,
with one tone (1000 Hz) being the standard stimulus
(P= 0.8) and the other being the infrequent target
stimulus (frequency: 2000 Hz; P= 0.2). Participants
were instructed to mentally count the target tones.
The interstimulus interval varied randomly between
2 and 3 s.
Participants were seated in an anatomic chair in a fara-
dized and light-attenuated room. The electrophysio-
logical signals were recorded by Ag/AgCl electrodes fixed
on the scalp at the F3, Fz, F4, C3, Cz, C4, P3, Pz and P4
sites, according to the International 10–20 System,
referred to linked mastoids and grounded at Fpz. The
bipolar electrooculogram was recorded from above and
below the left eye. All interelectrode impedances were
maintained below 3 kΩ. EEG signals and electro-
oculogram were filtered using a 0.01–30Hz. A notch filter
(50 Hz) was also applied. The data were digitized using
an analog/digital converter at a sampling rate of 1024Hz
and stored on a hard disk. A Mizar Sirius EEG-EP
Galileo NT multifunctional system (EB NEURO-
Firenze) was used.
ERP analysis
Trials containing eye movements were automatically
rejected. A further selection was performed in the offline
analysis to reject other kinds of artefacts according to the
clinical guidelines [20]. For each participant, all artefact-
free trials were averaged per stimulus (standard and tar-
get) and filtered with a low-pass digital filter of 20 Hz
for each stimulus. Scalp electrode activity was measured
at all electrode sites, of which Fz, Cz and Pz were
analysed.
The P3b amplitude and latency at Fz, Cz and Pz elec-
trode sites for target tones were measured from baseline
to peak using a 250–500 ms interval. Furthermore, the
P3b amplitude was also measured as the mean voltage
between 250 and 500 ms after target stimulus and P3b
timings were also quantified as midpoint latency, the
time point that divided the area under the curve into two
equal halves. It is known [21] that assessment of these
measures provides several advantages, that is compared
with the peak amplitude, the mean amplitude is not
biased by the number of trials.
Statistical analysis
The data were analysed using the IBM (Armonk,
New York, USA) SPSS Statistics software, version 20.
Analysis of variance (ANOVA) for continuous variables
and χ2 tests for dichotomous variables were used to
examine differences between BDI, BDII patients and
controls.
P3b maximum peak-to-peak latency and amplitude,
midpoint latency and the mean amplitude were analysed
separately using repeated-measures ANOVA, including
the between-subject factor grouping (BDI patients, BDII
patients and healthy controls) and the within-subject factor
electrodes location (Fz, Cz and Pz). Greenhouse–Geisser-
corrected P-values are reported. Bonferroni post-hoc tests
were used where relevant.
Results
Pharmacological treatments and other characteristics of
the participants are presented in Table 1. The three
groups (BDI, BDII and healthy controls) did not sig-
nificantly differ in age [F(2, 27)= 0.09; P= 0.92] and
educational level [F(2, 27)= 2.25; P= 0.13]. The two
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patient groups did not differ in age of onset [F(1, 18)
= 0.48; P= 0.50], duration of disease [F(1, 18)= 0.19;
P= 0.67], number of hospitalizations [F(1, 18)= 1.53;
P= 0.23], family history of BD [χ2 (1)= 0.83; P= 0.36]
and pharmacological treatment.
Repeated-measures ANOVA showed a significant loca-
tion effect in midpoint latency [F(1.87, 50.41)= 5.03;
P= 0.01]. Post-hoc comparisons showed that midpoint
latency was significantly longer at Pz than at Fz
(P= 0.03). No significant difference was observed for P3b
peak latency.
Repeated-measures ANOVA also showed a significant
location effect in both the peak amplitude
[F(1.67, 44.94)= 10.22; P< 0.001] and the mean ampli-
tude [F(1.35, 36.54)= 50.96; P< 0.001]. Post-hoc com-
parisons showed that the peak and mean amplitudes at
Pz were significantly higher than those at Fz (P< 0.001)
and Cz (P< 0.001) (see Fig. 1).
Finally, repeated-measures ANOVA showed a significant
groups effect in both peak amplitude [F(2, 27)= 12.72;
P< 0.001] and mean amplitude [F(2, 27)= 19.01;
P< 0.001]. Post-hoc comparisons showed that the peak
and mean amplitudes of BDI and BDII patients were
significantly lower than the peak and mean amplitudes of
healthy controls.
Discussion
The main aim of the present study was to investigate
P300 components in euthymic BDI and BDII patients
and matched controls.
Consistent with previous findings [12–15], patients with
BDI and BDII had significantly smaller P3b peak and
mean amplitudes than healthy controls. Different from
the hypothesis of the study, no significant differences
were found between BDI and BDII patients; this finding
confirms the results of Jahshan et al. [13], who reported
no significant differences in mismatch negativity and P3a
between BPI and BPII patients.
It is possible to speculate that the neurophysiological
patterns found in the present study might at least par-
tially reflect the presence of a mild selective cognitive
impairment in euthymic BDI and BDII patients [6]. In
particular, the smaller P3b amplitude may indicate a
difficulty in allocating the attentional resources during a
discriminative task. However, it is important to evidence
that our interpretation remains largely speculative
because of the absence of cognitive task/behavioural data
in the present study.
In the present study, a main effect of location was
observed for Pz electrodes. This is consistent with pre-
vious findings suggesting that parietal areas are crucial for
the generation of the scalp recorded P300 component
[22,23] and play an important role in different cognitive
processing such as working memory, attention and
executive function [5,6,24–26] that are known to be
potentially impaired in BD patients [5,6,27].
From a clinical point of view, our results raise some
relevant issues: the relapse rate for many psychiatric
disorders including BD is staggeringly high, indicating
that treatment methods combining psychotherapy with
pharmacological interventions are not entirely effective;
indeed, cognitive deficits have gained considerable
importance in the field as critical features of mental ill-
ness, and it is now believed that they might represent
valid therapeutic targets. Therefore, it may be hypothe-
sized that specific ‘ERP-oriented’ cognitive interventions
could be planned in addition to standard medications and
psychotherapies on the basis of each patient’s needs for
an ‘individualized’ or ‘personalized’ therapy that may
have the potential to reduce relapse rates and to improve
functional outcomes [11,28].
The most important limitation of the present study is the
small sample size, which makes it very difficult to draw
definitive conclusions from our data; the findings of the
present paper are promising, but they must be considered
only as preliminary. Future researches are needed to
assess potential neurophysiological differences in larger
samples of BDI and BDII patients and their association
with neuropsychological and clinical disturbances.
Table 1 Demographic variables, clinical characteristics and ERP
data of the sample
Mean (SD)
BDI (10) BDII (10) Control (10)
Age 47.70 ±8.90 48.50 ±14.26 46.20 ±13.05
Educational levela 13.44 ±3.68 16.14 ±2.27 12.70 ±3.71
Duration of diseasea 15.00 ±9.71 13.10 ±9.62 –
Number of
hospitalizations
3.30 ±6.06 0.90 ±0.99 –
Age of onseta 29.60 ±15.84 33.60 ±8.97 –
Familiarity to BD [N (%)] 3 (30) 5 (50) –
Pharmacological
treatment [N (%)]
–
Anticonvulsants 7 (70) 5 (50) –
Antipsychotics 6 (60) 7 (70) –
Antidepressants 3 (30) 5 (50) –
Two or more
psychotropic
medications [N (%)]
7 (70) 6 (60) –
Fz latency peak 379.18 ±21.439 414.58 ±59.76 373.48 ±28.23
Cz latency peak 383.68 ±23.45 400.57 ±62.28 350.90 ±59.07
Pz latency peak 391.18 ±28.77 397.81 ±57.87 372.07 ±30.29
Fz midpoint latency 368.18 ±23.94 360.31 ±27.10 355.96 ±32.18
Cz midpoint latency 369.17 ±26.91 370.44 ±30.73 365.14 ±29.91
Pz midpoint latency 370.53 ±17.60 368.37 ±20.46 377.34 ±22.43
Fz amplitude peak 5.11 ±2.67 4.64 ±3.10 10.30 ±4.39
Cz amplitude peak 4.87 ±4.11 6.68 ±4.24 13.69 ±7.80
Pz amplitude peak 6.17 ±3.22 9.68 ±5.66 16.78 ±8.32
Fz mean amplitude 2.19 ±0.76 1.83 ±0.51 4.94 ±2.14
Cz mean amplitude 3.78 ±1.56 2.63 ±1.59 8.40 ±3.73
Pz mean amplitude 6.86 ±1.94 8.48 ±6.14 13.38 ±2.86
BDI, bipolar disorder type I; BDII, bipolar disorder type II; BD, bipolar disorder;
ERP, event-related potential.
aYears.
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